Analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Aptevo Therapeutics Trading Down 3.1%
Shares of APVO opened at $0.31 on Friday. Aptevo Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $32.93. The firm has a 50-day simple moving average of $1.10 and a 200-day simple moving average of $60.80.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($4.39) EPS for the quarter, missing analysts’ consensus estimates of ($4.21) by ($0.18). Equities research analysts predict that Aptevo Therapeutics will post -15.84 earnings per share for the current fiscal year.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
See Also
- Five stocks we like better than Aptevo Therapeutics
- Investing in Travel Stocks Benefits
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- What Ray Dalio’s Latest Moves Tell Investors
- How to Most Effectively Use the MarketBeat Earnings Screener
- Amazon: Why May Is the Last Month to Get the Stock at a Discount
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
